• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Zyflo (zileuton)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Zyflo (zileuton)

  • Profile

Profile

Contact Information

Contact: Chiesi
Website: https://www.chiesiusa.com/products/

Currently Enrolling Trials

    Show More

    General Information

    Zyflo (zileuton) is an orally active inhibitor of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid.

    Zyflo is specifically indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

    Zyflo is supplied as a tablet for oral administration. The recommended dosage for the symptomatic treatment of patients with asthma is one 600-mg tablet four times a day for a total daily dose of 2400 mg. For ease of administration, Zyflo may be taken with meals and at bedtime. Hepatic transaminases should be evaluated prior to initiation of Zyflo and periodically during treatment.

    Mechanism of Action

    Zyflo acts as a leukotriene pathway inhibitor (LPI) by inhibiting the enzyme 5-lipoxygenase (5-LO). Zyflo inhibits the formation of leukotrienes. Leukotrienes are molecules that contribute to the inflammation, swelling (edema), bronchoconstriction (tightening of muscles wrapped around the outside of the airways) and mucus secretion seen in the airways of patients with asthma.

    Side Effects

    Adverse effects associated with the use of Zyflo may include, but are not limited to, the folloiwng:

    • headache
    • unspecified pain
    • abdominal pain
    • asthenia
    • dyspepsia
    • nausea
    • myalgia

    Clinical Trial Results

    In clinical trials involving patients with mild-to-moderate asthma who used daily inhaled beta-agonists, Zyflo decreased the percentage of patients requiring steroid rescues for worsening asthma compared to patients treated with placebo. Overall, the percentage of Zyflo patients requiring steroid rescue was 7 percent, compared with 18.7 percent of patients in the placebo group. This represents a reduction of 62 percent.

    In addition, patients receiving Zyflo also were able to reduce their use of inhaled beta-agonists. At the end of the six-month study, the number of beta-agonist puffs needed per day was 1.77 puffs, or 31 percent lower than baseline in Zyflo-treated patients; there was a 0.22 puff decrease in the placebo group. The reduction in the use of these medications was accompanied by improvements in lung function.

    Patients’ asthma symptoms improved by 36 percent, and night-time symptoms improved 31 percent in patients treated with Zyflo. For placebo-treated patients, improvements were 21 percent and 5 percent, respectively.

    Approval Date: 1997-01-01
    Company Name: Chiesi
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing